

OBIL/BSE/34/2019-20

04th December, 2019

To,
The Corporate Relations Department
BSE Limited,
P J Towers, 1st Floor,
Dalal Street,
Mumbai – 400 001
Scrip Code: **538019**

Dear Sir/Madam,

Ref: Scrip Code: **538019**

ISIN: **INE732P01018**

Sub: Submission of Revised Standalone Unaudited Financial Results for the Quarter and Half yearly ended on 30th September, 2019.

Ref: Your e-mail dated 03rd December, 2019 regarding the discrepancies in Standalone financial results for the Quarter and half yearly ended on 30th September, 2019


With reference to your e-mail dated 03rd December, 2019 regarding the discrepancies in Standalone financial results for the Quarter and half yearly ended on 30th September, 2019 -
“Cash Flow Statement for Standalone Results not received in Pdf”

In this regard, we hereby furnish the Revised Standalone Unaudited Financial Results for the Quarter and half yearly ended on 30th September, 2019, which includes Cash Flow Statement.


Kindly update the above in your records.

Thanking You.

For Oceanaa Biotek Industries Limited



Xavier Jeyaraj
Managing Director
DIN: 06896574





Oceanaa Biotech Industries Limited

CIN : L15549TN2005PLC057919

GSTIN : 33AAACO8057E1ZM

E : obil@oceanaabiotek.com

www.oceanaabiotek.com

OBIL/BSE/32/2019-2020

12th November, 2019

To,
The Corporate Relations Department
BSE Limited,
P J Towers, 1st Floor,
Dalal Street,
Mumbai – 400 001
Scrip Code: **538019**

Dear Sir/Madam,

Ref: Scrip Code: **538019**

ISIN: **INE732P01018**

Sub: Submission of Standalone Unaudited Financial Results for the Quarter and Half yearly ended on 30th September, 2019

This is to inform you that the meeting of the Board of Directors was held today, 12th November, 2019 inter alia, to consider and approve the Unaudited (limited reviewed) Financial Results for the quarter and half yearly ended on 30th September, 2019.

In this regard, the following documents are enclosed herewith:

- Standalone Unaudited Financial Results for the half year ended 30.09.2019 (Annexure I and Statement of Assets and Liabilities)
- Limited review report signed by the Statutory Auditor


The meeting commenced at 12:30 p.m. and concluded at 08:00 p.m.

Kindly update the above in your records.

Thanking You.

For Oceanaa Biotech Industries Limited


Xavier Jeyaraj
Managing Director
DIN: 06896574



M/S. OCEANAA BIOTEK INDUSTRIES LIMITED

CIN: L15549TN2005PLC057919

No.4B-1, Eastern Portion, 4th Floor, Centre Point Apartment, Sadhullah Street, T Nagar, Chennai - 600017


Unaudited Standalone Financial Results for the Quarter Ended 30th Sep 2019

in lakhs except earnings per share and share information/ data

S.No.	Particulars	Quarter Ended			Half-year Ended		Year Ended
		30-09-2019	30-06-2019	30-09-2018	30-09-2019	30-09-2018	31-03-2019
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from Operations						
	a) Sale of products	524.48	454.91	1,401.54	979.40	2,503.45	3,628.19
	b) Other Operating Revenues	-	-	-	-	-	-
	Total Revenue from Operations	524.48	454.91	1,401.54	979.40	2,503.45	3,628.19
2	Other Income	-	0.22	0.20	0.22	0.30	0.62
3	Total Income (1+2)	524.48	455.14	1,401.74	979.62	2,503.75	3,628.81
4	Expenses						
	a) Cost of Materials Consumed	-	162.25	-	162.25	-	2,645.57
	b) Purchase of Stock-in-Trade	171.28	-	807.36	171.28	1,391.06	-
	c) Changes in inventories of Finished Goods, Work-in-Progress and Stock-in-Trade"	6.69	24.23	0.61	30.92	118.55	587.47
	d) Employee Benefits Expense	28.97	40.06	68.10	69.02	131.04	192.87
	e) Depreciation and Amortisation Expense	54.45	53.85	78.92	108.30	157.81	250.43
	f) Finance Costs	2.08	2.01	3.02	4.10	6.13	11.50
	g) Other Expenses	123.80	55.63	209.97	179.43	391.81	1,997.51
	Total Expenses	387.27	338.02	1,167.98	725.29	2,196.40	5,685.35
5	Profit Before Exceptional Items and Tax (3 - 4)	137.22	117.11	233.76	254.33	307.35	(2,056.54)
6	Exceptional Items [Refer Note 4]	-	-	-	-	-	-
7	Profit Before Tax (5 + 6)	137.22	117.11	233.76	254.33	307.35	(2,056.54)
8	Tax Expense						
	Current Tax	9.09	7.35	67.42	16.44	88.64	-
	Deferred Tax Asset/ (Liability)	(2.08)	(1.31)	(2.90)	(3.39)	(58.25)	(51.22)
	Total	7.01	6.04	64.52	13.05	30.39	(51.22)
9	Profit After Tax (7 - 8)	130.20	111.08	169.24	241.28	276.96	(2,005.32)
10	Other Comprehensive Income						
	"a) Items not to be reclassified to profit or loss in subsequent periods"	-	-	-	-	-	7.47
	"Re-measurement Gains and (Losses) on Defined Benefit Obligations (Net) and Net (Loss)/ Gain on FVTOCI Equity Securities"	-	-	-	-	-	-
	Income Tax Effect	-	-	-	-	-	-
	"b) Items to be reclassified to profit or loss in subsequent periods"	-	-	-	-	-	-
	Net movement on cash flow hedges	-	-	-	-	-	-
	Income Tax Effect	-	-	-	-	-	-
	Other Comprehensive Income for the period	-	-	-	-	-	7.47
11	Total Comprehensive income (9 + 10)	130.20	111.08	169.24	241.28	276.96	(1,997.85)
12	Paid-up Equity Share Capital (Face Value of 10 Each)	135,652,750	135,652,750	135,652,750	135,652,750	135,652,750	135,652,750
13	Earnings Per Share (Face Value Rs. 10/- per Share) - Not Annualised						
	- Basic (in Rs.)	0.96	0.82	1.25	1.78	2.04	(14.78)
	- Diluted (in Rs.)	0.96	0.82	1.25	1.78	2.04	(14.78)

Notes:

- The un-audited Financial results were reviewed by the Audit Committee and taken on record by the Board of directors at their meeting held on 12th Nov, 2019
- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (IND AS) prescribed under Sec 133 of the Companies Act 2013 and other recognised accounting practices and policies to the extent applicable.
- Figures of the previous period/year are reclassified /regrouped or rearranged wherever necessary to make it comparable.
- There are no separate reportable segments for the three months ended Jun 2019 as per Accounting Standard 17 on segment reporting notified under the Companies (Accounting Standard) Rules 2014.
- There were two unresolved Investor complaint pending against the Company.
- All the financial numbers presented above are prepared as per the IND AS.




For and on Behalf of Board of Directors

[Signature]

Thomas Xavier Jeyaraj
Managing Director
DIN: 06896574



Place: Chennai
Date : 12-Nov-2019

M/S. OCEANAA BIOTEK INDUSTRIES LIMITED			
CIN: L15549TN2005PLC057919			
STATEMENT OF ASSETS AND LIABILITIES			
As at 30th Sep 2019			
PARTICULARS		30th Sep 2019	31st March 2019
		Amt.Rs.	Amt.Rs.
A	ASSETS		
1	Non-current assets		
	(a) Property, Plant and Equipment	1,558.06	1,666.36
	Total Non-Current Assets	1,558.06	1,666.36
2	Current assets		
	(a) Inventories	23.37	54.28
	(b) Financial Assets		
	(i) Trade Receivables	1,405.07	1,061.05
	(ii) Cash and cash equivalents	10.68	11.42
	(iii) Short-term loans & advances	59.64	55.63
	(c) Current Tax Assets	0.04	0.04
	(d) Other current assets	1,081.55	1,070.63
	Total Current Assets	2,580.35	2,253.05
	TOTAL ASSETS	4,138.41	3,919.42
B	EQUITY AND LIABILITIES		
1	Equity		
	(a) Equity Share capital	1,356.53	1,356.53
	(b) Other Equity	1,420.14	1,169.79
	Total Equity	2,776.66	2,526.32
2	LIABILITIES		
	Non-current liabilities		
	(a) Borrowings	89.35	102.69
	(b) Provisions	-	3.42
	(c) Deferred tax Liabilities (Net)	-11.32	1.23
	Total Non-Current Liabilities	78.03	107.34
	Current Liabilities		
	(a) Financial Liabilities		
	(i) Trade Payables	372.43	374.79
	(ii) Other Financial liabilities	30.44	31.79
	(b) Other current liabilities	19.38	30.74
	(c) Provisions	861.47	848.43
	Total Current Liabilities	1,283.72	1,285.76
	Total Liabilities	1,361.75	1,393.09
	TOTAL EQUITY AND LIABILITIES	4,138.41	3,919.42



Thomas Xavier Jeyaraj
Managing Director
DIN: 06896574

Place: Chennai
Date: 12-Nov-2019

M/s.Oceanaa Biotek Industries Limited CIN:L15549TN2005PLC057919 No.4B-1, Eastern Portion, 4th Floor, Centre Point Apartment, Sadhullah Street, T Nagar, Chennai - 600017 CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30TH SEPTEMBER 2019		
Particulars	As at 30-Sep-19 INR	As at 30-Sep-18 INR
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net profit before taxes	254.33	307.35
Adjustment for:		
Depreciation	108.30	157.81
Interest Income		-
Operating profit before working capital changes	362.63	465.16
Adjustment for increase/ (-) decrease in		
Inventory	30.92	118.55
Trade receivables	(344.02)	(646.51)
Tax Assets	-	0.09
Loans, advances and other current assets	(10.93)	122.70
Trade payables	(2.36)	(33.33)
Other Financial liabilities	(1.35)	(0.39)
Other current liabilities	(11.37)	(35.73)
Short term provisions	(3.42)	88.54
Long term provisions	13.04	(16.56)
DTA	-	(58.25)
Cash generated from / (used in) operations	(329.48)	(460.91)
Exceptional Item		
Less: Current year provision / Taxes paid	16.44	88.64
Add: DTA	(0.10)	58.25
Net cash flow from operating activities (A)	16.61	(26.14)
B. CASH FLOW FROM INVESTING ACTIVITIES		
Sale for fixed assets	-	-
Loss of Fixed Assets	-	(2.07)
Interest income	-	-
Other Financial Assets	(4.01)	(0.86)
Net cash flow/used in from investing activities (B)	(4.01)	(2.93)
C. CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from long term borrowings (Net)	(13.34)	(12.31)
Repayment of short term borrowings	-	-
Premium on equity shares	-	-
Issue of equity shares	-	-
Dividend paid	-	-
Net cash flow from financing activities (C)	(13.34)	(12.31)
D. Net increase/decrease in cash and cash equivalents (A+B+C)	(0.74)	(41.38)
Cash and cash equivalents (Opening balance)	11.42	48.90
Cash and cash equivalents (Closing balance)	10.68	7.52
Components of cash and cash equivalents:		
Cash on hand	5.04	0.13
Balance with Banks	5.64	7.39
Term deposits with bank	-	-
The accompanying notes form an integral part of the Standalone financial statements. This is the Statement of Cash Flows referred to in our report of even date.		
<div style="display: flex; justify-content: space-between; align-items: center;"> <div> Place: Chennai Date: 12-Nov-2019 </div> <div style="text-align: center;">  </div> <div>  Thomas Xavier Jeyaraj Managing Director DIN: 06896574 </div> </div>		

Limited Review Report for the Quarter Ending 30th September 2019

To
The Board of Directors
M/s. OCEANAA BIOTEK INDUSTRIES LIMITED
No.4B-1, Eastern Portion, 4th Floor,
Centre Point Apartment, Sadhullah Street,
T Nagar, Chennai - 600017

We have reviewed the accompanying statement of audited financial results (the "statement") of M/s. OCEANAA BIOTEK INDUSTRIES LIMITED ("the Company") for the period ended 30.09.2019 attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No CIR/CFD/FAC/62/2016 dated July 5, 2016.



The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS) 34 "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 read with SEBI circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 is the responsibility of the Company's management and has been approved by the Board of Directors of the Company. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have performed our audit and accordingly, we do express our opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of audited financial results prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No CIR/CFD/FAC/62/2016 dated July 5, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For ABHAY JAIN & CO.
Chartered Accountants
FRN: 0000008S

Date: 12/11/2019
Place: Chennai
UDIN: 19070224AAAACE5182


(A.K. Jain)
MNO: 070224


To

The Board of Directors,

Oceanaa Biotech Industries Limited

No.4B-1, Eastern Portion, 4th Floor,
Centre Point Apartment, Sadhullah Street,
T Nagar, Chennai - 600017

Dear Sir/Madam,


We hereby confirm the following in respect of the unaudited financial statements for the Quarter and half yearly ended on 30th September, 2019 being presented before the Board at the meeting to be held on 12th November, 2019.


- (1) That to the best of our knowledge, the financial results do not contain any false or misleading statement of figures.
- (2) That to the best of our knowledge, the financial results do not omit any material fact which may make the statements or figures contained therein misleading.

Yours sincerely

Place: Chennai

Date: 12.11.2019




T Xavier Jeyaraj
Managing Director
DIN: 06896574